Latest Conference Coverage

Gemfibrozil Shows Promise in Predementia Alzheimer Disease Metabolic and CVD Outcomes

The agent, which is FDA-approved for hyperlipidemia, showed significant improvements in plasma glucose, lipid levels, and trends in cardiovascular imaging biomarkers.

Ongoing Research in MS Differentiation: Oliver Tobin, MBBCh, BAO, PhD

The associate professor of neurology at Mayo Clinic Rochester discusses technological advancements and research efforts in relation to differential multiple sclerosis.

Biomarkers and MRI Use in Patients With MS: Oliver Tobin, MBBCh, BAO, PhD

The associate professor of neurology at Mayo Clinic Rochester, commented on biomarkers for identifying MS in patients, as well as the significance of new MS consensus guidelines.

Identifying Atypical Forms, Presentations of Demyelinating Disease: Oliver Tobin, MBBCh, BAO, PhD

The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.

Mayo Clinic: Institutional Perspectives in Neurology, Chaired by Brian G. Weinshenker, MD

Chaired by Brian G. Weinshenker, MD, the presentations also feature Mayo Clinic experts W. Oliver Tobin, MBBCh, BAO, PhD; Jessica Stulc, MD, MPH; and Orhun H. Kantarci, MD. [WATCH TIME: 1 hour, 30 minutes]

Nerve Blocks for the Treatment of COVID-19 Headache: Aarushi Suneja, MD

The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.

Improving Use of Telemedicine in Minority Communities: Aarushi Suneja, MD; Zubair Ahmed, MD

The duo from Cleveland Clinic discussed their presentation from AHS 2021 regarding the effects of COVID-19 on access to telemedicine visits among minorities.

Next Steps in Alzheimer Disease Research: Clive Ballard, MD

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

Most Patients Report Positive Lemborexant Treatment Effect in Insomnia

Data presented at SLEEP 2021 from Study 303 suggest that long-term use of lemborexant is well received by patients, who reported that the agent helped them fall asleep and improved total sleep time.

AHS 2021 Takeaways and the State of Migraine Research: Richard B. Lipton, MD

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

Treating Migraine With External Trigeminal Nerve Stimulation

Deena Kuruvilla, MD, the medical director of the Westport Headache Institute spoke to the potential of e-TNS in the treatment of migraine overall and which gaps in care that it might fill.

Clinical Takeaways From INP104 Data in Migraine: Sheena K. Aurora, MD

The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.

Greatest Unmet Needs in Sleep Disorder Care: Asim Roy, MD

The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.

Daridorexant Shows Efficacy as Insomnia Therapy With Evidence of No Withdrawal Effects

The Idorsia dual orexin receptor antagonist was accepted by the FDA for review in March 2021 and has shown efficacy in a number of SLEEP 2021 poster presentations.

FT218’s Effect on BMI Regardless of Stimulant Use: Asim Roy, MD

The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.

Future Areas of Progress for Sleep Disorder Care: Asim Roy, MD

The medical director of the Ohio State Sleep Medicine Institute detailed the progress made within the sleep disorder field in recent years and where it can turn to next.

NeuroVoices: Michael J. Thorpy, MD, on FT218, State of Current Sleep Care

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.

Novel Approaches to Challenges in Treating Migraine: Carrie Dougherty, MD, FAHS

CBT-I Headlines AASM Guidelines for Chronic Insomnia

The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.

Solriamfetol Efficacious, Easily Titrated in Patients Initiating Treatment for Narcolepsy

Results from the START study of medication switching in narcolepsy were presented at the 2021 SLEEP Annual Meeting.

Telemedicine Produces Meaningful Migraine Improvement, Galcanezumab Shows No Wearing Effect, CGRPs All Significant Improve MMDs

Neurology News Network for the week ending June 12, 2021.

Pitolisant Further Demonstrates Clinical Benefit on Excessive Daytime Sleepiness, Cataplexy

The FDA-approved agent demonstrated meaningful reduction in the frequency of cataplexy attacks in adults with narcolepsy, including patients with a high symptom burden.

FT218 Efficacious in Treating Narcolepsy Subtypes

Data presented at SLEEP 2021 also showed the treatment was associated with significant weight loss and reduction in BMI compared to placebo.

Investigating INP104 for Migraine Treatment: Carrie Dougherty, MD, FAHS

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.

Clinically Meaningful Improvements in Migraine Achievable With Synchronous Telemedicine

The findings support previous data that showed no differences between telemedicine and traditional consultations in HIT-6 assessment scores over a long-term period.

Concomitant Use of Ubrogepant With CGRP Monoclonal Antibodies: Richard B. Lipton, MD

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

Rimegepant Achieves Migraine Prevention After 1 Week of Treatment

A post-hoc analysis of the phase 2/3 trial of rimegepant revealed early and sustained efficacy compared to placebo, with significant reductions in weekly migraine days.

Nasal Delivery of DHE for Migraine: Carrie Dougherty, MD, FAHS

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the advantages of INP104 over other forms of dihydroergotamine.

New Migraine Burden Index Proves Accurate, Strongly Correlates With Patient Satisfaction

Investigators conducted a 9-month study that demonstrated the correlation of the MBI, calculated as the sum of headache days times the maximum intensity of headache on each headache day, with satisfaction of migraine status.

Despite Slight Differences, Preventive Migraine Therapies Demonstrate High Efficacy

Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.